Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm
Author:
Publisher
European Respiratory Society (ERS)
Subject
Pulmonary and Respiratory Medicine
Reference32 articles.
1. Lung cancer: current therapies and new targeted treatments;Hirsch;Lancet,2017
2. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial;Vansteenkiste;Lancet Oncol,2016
3. Enhancement of Antitumor Immunity by CTLA-4 Blockade
4. Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
5. Les inhibiteurs des freins immunitaires (anticorps anti-PD1 et anti-PDL1), une nouvelle arme thérapeutique dans les cancers bronchiques non à petites cellules [Immune checkpoint inhibitors (antibodies to PD1 and PD-L1), a new therapeutic weapon against non-small cell bronchial carcinoma];Berghmans;Rev Mal Respir,2018
Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Induction chemotherapy backbone in frail patients with advanced NSCLC treated with chemotherapy plus pembrolizumab: a single institution retrospective audit of dose intensities from modified regimens.;Journal of Chemotherapy;2024-08-06
2. Expression patterns of novel immunotherapy targets in intermediate- and high-grade lung neuroendocrine neoplasms;Cancer Immunology, Immunotherapy;2024-05-02
3. Inhibition of CSF-1R and IL-6R prevents conversion of cDC2s into immune incompetent tumor-induced DC3s boosting DC-driven therapy potential;Cell Reports Medicine;2024-02
4. Radiotherapy to reinvigorate immunotherapy activity after acquired resistance in metastatic non-small-cell lung cancer: A pooled analysis of two institutions prospective phase II single arm trials;Radiotherapy and Oncology;2024-01
5. Impact of Neoadjuvant Immune Checkpoint Inhibitors on Surgery and Perioperative Complications in Patients With Non–small-cell Lung Cancer: A Systematic Review;Clinical Lung Cancer;2023-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3